Calliditas Therapeutics AB American Depositary Shares
CALT
CALT was delisted on the 20th of September, 2024.
19 hedge funds and large institutions have $18.8M invested in Calliditas Therapeutics AB American Depositary Shares in 2024 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 9 increasing their positions, 1 reducing their positions, and 3 closing their positions.
800% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 1
10% less funds holding
Funds holding: 21 → 19 (-2)
14% less capital invested
Capital invested by funds: $21.8M → $18.8M (-$3.02M)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
95% less call options, than puts
Call options by funds: $32K | Put options by funds: $705K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$306K |
| 2 |
Morgan Stanley
New York
|
+$106K |
| 3 |
Wells Fargo
San Francisco,
California
|
+$50.3K |
| 4 |
Optiver Holding
Amsterdam,
Netherlands
|
+$34.6K |
| 5 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
+$33.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$24.5K |
| 2 |
JP Morgan Chase
New York
|
-$15.6K |
| 3 |
CG
Cutler Group
San Francisco,
California
|
-$2K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
-$1.51K |
CALT Hedge Fund Activity: Q1 2024 in Review
19 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Calliditas Therapeutics AB American Depositary Shares (CALT) for Q1 2024, worth a combined $18.8M — down 14% from $21.8M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of CALT and 2 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 9 added.
The largest buyer was Citadel Advisors, adding an estimated $306K. The largest seller was UBS Group, exiting entirely with an estimated $24.5K sold.
- 19 institutional investors held Calliditas Therapeutics AB American Depositary Shares (CALT) as of Q1 2024, down from 21 in Q4 2023.
- Funds reported $18.8M of Calliditas Therapeutics AB American Depositary Shares stock for Q1 2024, down 14% quarter-over-quarter.
- 2 funds opened new Calliditas Therapeutics AB American Depositary Shares positions in Q1 2024 and 3 closed out, a net change of -1 holder.
- The largest Calliditas Therapeutics AB American Depositary Shares buyer in Q1 2024 was Citadel Advisors, an estimated $306K added.
- The largest Calliditas Therapeutics AB American Depositary Shares seller in Q1 2024 was UBS Group, an estimated $24.5K sold.
Based on aggregated 13F filings for Q1 2024.